Modulation of the GABAergic pathway for the treatment of fragile X syndrome
Reymundo Lozano,1,2 Emma B Hare,1,2 Randi J Hagerman1,2 1MIND Institute, 2Department of Pediatrics, UC Davis Medical Center, Sacramento, CA, USA Abstract: Fragile X syndrome (FXS) is the most common genetic cause of intellectual disability and the most common single-gene cause of autism. It is cau...
Enregistré dans:
Auteurs principaux: | Lozano R, Hare EB, Hagerman RJ |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2014
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/93aa0c19c4ba410d9e40f0e9d2a11c33 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Update on the role of antipsychotics in the treatment of Tourette syndrome
par: Huys D, et autres
Publié: (2012) -
Treatment of Lennox-Gastaut syndrome: overview and recent findings
par: Kenou van Rijckevorsel
Publié: (2008) -
Exploring diazoxide and continuous glucose monitoring as treatment for Glut1 deficiency syndrome
par: Santhi N. Logel, et autres
Publié: (2021) -
Influence of drug treatment with antidepressants and antipsychotics on plasma urea levels
par: Lozano Ortiz R
Publié: (2012) -
Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine
par: Lindquist S, et autres
Publié: (2011)